Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology

• Published in: American journal of physiology: endocrinology and metabolism 2023-11, Vol.325 (5), p.E649-E660
• Main Authors: González-Salvatierra, Sheila, García-Fontana, Beatriz, Martínez-Heredia, Luis, Lacal, Jesus, Andújar-Vera, Francisco, Sanabria-de la Torre, Raquel, Moratalla-Aranda, Enrique, Lozano-Alonso, Silvia, García-Fontana, Cristina, Muñoz-Torres, Manuel
• Format: Article
• Language: English
• Subjects: Atherosclerosis - metabolism; Biomarkers - metabolism; Cardiovascular Diseases - metabolism; Diabetes Mellitus, Type 2 - metabolism; Humans; Insulin Resistance; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle - metabolism; Triglycerides - metabolism
• ISSN: 0193-1849; 1522-1555
• DOI: 10.1152/ajpendo.00320.2023

Osteoglycin, a fundamental proteoglycan within the vascular extracellular matrix, is expressed in vascular smooth muscle cells (VSMCs). Type 2 diabetes (T2D) is associated with cardiovascular disease (CVD) but the role of osteoglycin in the development of CVD is controversial to date. Therefore, our aims are to determine and compare the level of osteoglycin in T2D patients with/without CVD versus control subjects both at serum and vascular tissue and to analyze in vitro role of osteoglycin in VSMCs under calcified conditions. For this, serum osteoglycin levels were determined by enzyme-linked immunosorbent assay (ELISA) in 117 controls and 129 patients with T2D (46 with CVD and 83 without CVD), revealing a significant increase in patients with T2D compared with controls. Osteoglycin level was not an estimator of CVD but correlated with markers of insulin resistance (triglycerides and triglycerides/high-density lipoprotein cholesterol index) in patients with T2D. At the vascular level, osteoglycin expression was assessed by RT-qPCR and immunohistochemistry, and no significant differences were observed between calcified arteries from patients with T2D and noncalcified arteries from controls. In vitro experiments using VSMCs (mock and overexpressing osteoglycin) under calcifying conditions were performed to analyze the osteoglycin function. The overexpression of osteoglycin in VMSCs under calcifying conditions revealed an increase of cell proliferation without effect on apoptosis and an upregulation of the expression of autotaxin ( ) involved in inflammatory processes. In conclusion, osteoglycin could play a role in glycemic homeostasis, being a potential biomarker of insulin resistance in patients with T2D. Furthermore, osteoglycin could indirectly participate in the development of atherosclerosis through its regulatory effect on and by proliferating VSMCs. This study uncovers an increase of serum osteoglycin levels in patients with type 2 diabetes, which does not appear to be associated with the development of atherosclerosis, but rather with insulin resistance in this population. Overexpression of osteoglycin increased proliferation and upregulated the expression of autotaxin in vascular smooth muscle cells within calcified environments. Osteoglycin could be a biomarker of insulin resistance for type 2 diabetes and could be indirectly involved in the development of atherosclerosis.